摘要
目的探讨华氏巨球蛋白血症(Waldenstr m macroglobulinemia,WM)的临床特点。方法回顾性分析22例WM患者症状体征以及检查治疗预后。结果5年生存率为67%,不同Morel预后分组生存曲线差异有统计学意义。结论WM的疾病过程具有低度恶性B细胞淋巴瘤的特点,Morel预后评分对决定治疗策略及评价疗效有重要意义。
Objective To analyze the clinical manifestations, diagnosis, therapy and prognosis of Waldenstroem macrnglobulinemia（ WM）. Methods 22 patients with Waldenstroem macrnglobulinemia were studied retrospectively. Survival curves were drawn using the Kaplan-Meire product limit method and compared by using the log-rank test.Proportions were compared with the X2 test.Results The group＇s survival rate of five years was 67 %. 22 patients were divided into 3 subsets （low risk, intermediate risk, and high risk ）relied on staging system developed by Morel, significant differences were manifested among different subsets. Conclusion The clinical sourse of Waldenstroem macrnglobulinemia is typically indolent. The Morel＇ s Categories for survival might help to select patients with for treatment and to evaluate therapeutic result.
出处
《四川医学》
CAS
2007年第2期161-163,共3页
Sichuan Medical Journal
关键词
华氏巨球蛋白血症
治疗
预后
Waldenstroem macroglobulinemia
treatment
prognosis
